EphA4 inhibitors as neuroprotective agents
US9629830B2 · kind B2 · utility
2Cited by
0References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 17, 2014 |
| Grant date | Apr 25, 2017 |
| Priority date | — |
| Expiry date | Jul 17, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/20
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided is the discovery of the role of EphA4 signaling in neurodegenerative disorders involving β-amyloid induced neurotoxicity such as Alzheimer's Disease. New therapeutic methods, therapeutic agents, and kits for treating diseases caused or exacerbated by overactivated EphA4 signaling are provided. Also provided are methods for identifying additional compounds as therapeutic agents useful for treating conditions involving overly active EphA4 signaling.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.